🌍·2d agodiscovery
Akeso, Summit’s ivonescimab tops Keytruda in lung cancer survival, with strong data in PD-L1-high patients
Publisher
F
Fierce Pharma
Global
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Fierce Pharma
- Region
- Global
- Scope
- discovery
- Published
- September 13, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: Fierce Pharma
Scope: discovery
Related coverage
More related coverage
marketbeat.com/13h ago
Promising Biotech Stocks To Follow Today - September 14th
Petrie-Flom Center/14h ago
A Path to Stability at FDA?
Lampoon Magazine/14h ago
Extracting CBD: from artisanal practice to industrial production
marketscreener.com/14h ago